Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 361

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 361
---
 $1.00  
    $0.52 
  
    Quarter Ended December 31, 2024 
    $0.84  
    $0.50 

Holders 

On March 31, 2025, the closing price of our stock
was $0.78 per share and we had 653 stockholders of record. This number does not include beneficial owners whose shares are held by nominees
in street name.

Transfer Agent

The transfer agent of our common stock is Issuer Direct
Corporation, having an office at One Glenwood Avenue, Suite 1001, Raleigh, NC 27603; their phone number is (801) 272-9294.

Dividend Policy

We paid no dividends during the years ended December
31, 2024 and 2023, and we do not expect to pay any cash dividends in the foreseeable future. We expect to retain any potential future
earnings, if any, to fund our research and development efforts.

 27 

Equity Compensation Plan Information

The following table summarizes our compensation plans
under which our equity securities are authorized for issuance as of December 31, 2024:

          Plan Category 
    (a) Number of Securities to be Issued Upon the
                                                                                                                                                                                 Exercise of Outstanding Options, Warrants and Rights  
    (b) Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights ($/share)  
    (c) Number of Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) 
  
    Equity compensation plans approved by stockholders 
     510,513(1) 
     –(2) 
     1,137,409(3)
  
    Equity compensation plans not approved by stockholders 
     –  
     –  
     – 
  
    Total 
     510,513(1) 
     –(2) 
     1,137,409(3)

 ______________________

    (1)
    Represents restricted stock units (“RSUs”) granted under our stockholder approved equity compensation plan referred to as the 2020 Omnibus Incentive Plan (“2020 Plan”).

    (2)
    Weighted-average exercise price is not shown as there is no exercise price for RSUs.

    (3)
    On the first anniversary date from the adoption date of the 2020 Plan (or